Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Colloquium supported by Daiichi Sankyo Europe GmbH - Relapsed/Refractory FLT3-ITD mutated Acute Myeloid Leukemias (AML)

Recent results with FLT3 Inhibitors in FLT3-ITD positive Relapsed/Refractory AML and future development

Date

29 Sep 2019

Session

ESMO Colloquium supported by Daiichi Sankyo Europe GmbH - Relapsed/Refractory FLT3-ITD mutated Acute Myeloid Leukemias (AML)

Topics

Tumour Site

Leukaemias

Presenters

Jorge Cortes

Authors

J. Cortes

Author affiliations

  • Hematology, Georgia Cancer Center, 29841 - North Augusta/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.